Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|
Income Statement | |||||
Total Revenue | 7.68M | 6.70M | 9.69M | 7.31M | 10.53M |
Gross Profit | 7.14M | 6.06M | 8.99M | 6.65M | 9.47M |
EBITDA | -13.09M | -36.69M | -24.28M | -32.47M | -29.20M |
Net Income | -13.51M | -36.48M | -28.24M | -37.59M | -34.33M |
Balance Sheet | |||||
Total Assets | 14.92M | 23.11M | 26.54M | 42.19M | 41.32M |
Cash, Cash Equivalents and Short-Term Investments | 9.73M | 18.25M | 19.11M | 27.76M | 21.04M |
Total Debt | 889.00K | 795.00K | 1.17M | 1.82M | 2.89M |
Total Liabilities | 5.35M | 6.50M | 8.64M | 7.76M | 12.12M |
Stockholders Equity | 9.57M | 16.61M | 17.90M | 34.42M | 29.19M |
Cash Flow | |||||
Free Cash Flow | -14.88M | -30.67M | -27.70M | -34.00M | -24.23M |
Operating Cash Flow | -14.77M | -30.60M | -27.50M | -28.23M | -18.71M |
Investing Cash Flow | -107.00K | -43.00K | -158.00K | -5.76M | -5.51M |
Financing Cash Flow | 6.44M | 29.10M | 19.48M | 40.79M | 21.82M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
75 Outperform | £126.70M | 114.52 | 11.82% | ― | 13.76% | 31.36% | |
71 Outperform | £28.13M | 32.49 | ― | 1.58% | ― | ||
66 Neutral | £137.03M | 40.49 | 11.59% | 0.61% | 15.67% | 25.62% | |
61 Neutral | $35.52B | 8.84 | -11.06% | 1.87% | 8.55% | -8.14% | |
61 Neutral | £53.56M | ― | -16.92% | ― | -1.09% | -6.65% | |
51 Neutral | £25.39M | ― | -268.88% | ― | 1.65% | 29.02% | |
45 Neutral | £12.63M | ― | -15.60% | ― | -5.21% | 76.14% |
Cirata plc has completed the divestment of its DevOps assets to BlueOptima Ltd, receiving an initial $2.5 million with a potential additional $1 million contingent on customer transfers. This move allows Cirata to concentrate on its core Data Integration business, which is pivotal for its growth strategy.
The most recent analyst rating on (GB:CRTA) stock is a Buy with a £93.00 price target. To see the full list of analyst forecasts on Wandisco stock, see the GB:CRTA Stock Forecast page.
Cirata plc has reported a significant 58% year-over-year growth in bookings for the first half of the fiscal year 2025, with a notable 244% increase in data integration sales. The company has divested its DevOps assets to BlueOptima for up to $3.5 million, allowing Cirata to focus on its core data integration business. This strategic move is expected to enhance financial flexibility and support growth initiatives. Despite a decline in total Q2 bookings, Cirata has reduced its cash burn and strengthened its sales execution with the appointment of a new Chief Revenue Officer. The company remains optimistic about its growth trajectory, particularly in the data integration sector, and aims to leverage partnerships such as the one with Microsoft Azure to expand its market reach.
The most recent analyst rating on (GB:CRTA) stock is a Buy with a £93.00 price target. To see the full list of analyst forecasts on Wandisco stock, see the GB:CRTA Stock Forecast page.
Cirata plc has secured a $700,000 two-year contract renewal for its Data Integration software with a leading Canadian bank, demonstrating continued trust in its Live Data Migrator technology. This deal, facilitated through Google Marketplace, underscores Cirata’s strong positioning in the data integration sector and its ability to meet the complex needs of major financial institutions.
The most recent analyst rating on (GB:CRTA) stock is a Buy with a £93.00 price target. To see the full list of analyst forecasts on Wandisco stock, see the GB:CRTA Stock Forecast page.
Cirata has appointed Sarah Rolls as a Non-Executive Director and Chair of the Audit and Risk Committee. With extensive experience in finance, risk management, and governance from her roles at Sage Group and Tate & Lyle, Sarah’s expertise is expected to significantly benefit Cirata’s board and support the company’s ongoing development.
The most recent analyst rating on (GB:CRTA) stock is a Buy with a £93.00 price target. To see the full list of analyst forecasts on Wandisco stock, see the GB:CRTA Stock Forecast page.